Thus, in experimental models of chronic myeloid leukemia (CML), genetic ablation of FBXW7 in quiescent leukemic stem cells reprograms them to re-enter the cell cycle and the cells become susceptible to imatinib (186). The gene discussed is FBXW7; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.